Article
Nearly 10% of women treated with herceptin were found to be susceptible to heart risks, which reversed once treatment was halted.
As many as one in 10 women taking the breast cancer drug trastuzumab (Herceptin) will experience some type of heart problem, according to new research.
The good news from this study is that these problems typically reverse once treatment is finished.
"The overall message here is one of tremendous reassurance," said study researcher Dr. Brian Leyland-Jones, vice president of molecular and experimental medicine at Avera Cancer Institute in Sioux Falls, S.D.
Journal of Clinical Oncology
The study was published June 9 in the online. Roche, the maker of Herceptin, provided research funding. Some of the study's co-authors work for Roche or are advisers or consultants.
Report: http://bit.ly/1llbx8l
Source: WebMD
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman